Chandrasinghe Pramodh Chitral, Ediriweera Dileepa Senajith, Hewavisenthi Janaki, Kumarage Sumudu, Deen Kemal Ismail
Department of Surgery, North Colombo Teaching Hospital, Ragama, Sri Lanka,
Indian J Gastroenterol. 2014 May;33(3):249-53. doi: 10.1007/s12664-013-0406-2. Epub 2013 Sep 19.
Lymph node status is important in staging colorectal cancer (CRC). Presence of metastatic nodes differentiates stage III from stage II. The role of adjuvant therapy is still unclear in stage II CRC. Inadequate node sampling may result in inaccurate staging.
Records of 131 patients with stages II and III CRC who underwent curative resection, having five or more lymph nodes harvested from the specimen, were prospectively followed up and analyzed. The Kaplan-Meier method was used to analyze survival, based on groups of serially ascending values of lymph nodes harvested. Regression analysis was performed by Cox proportional hazards ratio model with right-censored CRC survival data at a 10 % significance level. The effect of nodal harvest on survival was adjusted for age, sex, preoperative carcinoembryonic antigen (CEA) level, neoadjuvant chemoradiation, pathological tumor stage, histological type, differentiation, margin positivity, angioinvasion, perineural invasion, and lymphovascular infiltration.
The total population showed improved survival with 14 or more nodes harvested (p= 0.005). For both rectal (n= 83; p= 0.03) and colon cancers (n= 46; p= 0.08), most significant survival benefits were seen with over 14 nodes harvested, irrespective of the stage. With multiple regression analysis, advanced age (p= 0.003), male sex (p= 0.017), lymphovascular infiltration (p= 0.015), and preoperative CEA levels (p= 0.096) were found to be other significant factors. The lymph node effect remained significant (HR = 0.19, p= 0.004) after adjusting for the above factors.
A lymph node harvest of 14 or more resulted in better survival outcome from CRC in this population. Staging of the disease could be accurate with increased nodal harvesting.
淋巴结状态在结直肠癌(CRC)分期中很重要。转移淋巴结的存在可区分III期和II期。辅助治疗在II期CRC中的作用仍不明确。淋巴结采样不足可能导致分期不准确。
对131例接受根治性切除的II期和III期CRC患者的记录进行前瞻性随访和分析,这些患者的标本中采集了5个或更多淋巴结。采用Kaplan-Meier方法基于采集的淋巴结数量连续递增分组分析生存率。采用Cox比例风险模型对CRC生存数据进行右删失回归分析,显著性水平为10%。针对年龄、性别、术前癌胚抗原(CEA)水平、新辅助放化疗、病理肿瘤分期、组织学类型、分化程度、切缘阳性、血管侵犯、神经周围侵犯和淋巴管浸润等因素,对淋巴结采集对生存的影响进行校正。
总体人群中,采集14个或更多淋巴结时生存率提高(p = 0.005)。对于直肠癌(n = 83;p = 0.03)和结肠癌(n = 46;p = 0.08),无论分期如何,采集超过14个淋巴结时均观察到最显著的生存获益。通过多元回归分析,发现高龄(p = 0.003)、男性(p = 0.017)、淋巴管浸润(p = 0.015)和术前CEA水平(p = 0.096)是其他显著因素。校正上述因素后,淋巴结效应仍然显著(HR = 0.19,p = 0.004)。
在该人群中,采集14个或更多淋巴结可使CRC患者获得更好的生存结局。增加淋巴结采集可使疾病分期更准确。